Grail says FDA advisory panel meets Sept. 23 on Galleri test PMA review

Reuters2026/08/07 15:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Grail faces an FDA advisory committee review on Sept. 23, 2026 for its Galleri multi-cancer early detection blood test PMA.
The PMA was submitted on Jan. 29, 2026. The FDA granted Galleri Breakthrough Device designation in 2018.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608071105PR_NEWS_USPR_____LA18073) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Grail says FDA advisory panel meets Sept. 23 on Galleri test PMA review

You may also like

Crypto prices